BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31902674)

  • 1. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.
    Wang BD; Ceniccola K; Hwang S; Andrawis R; Horvath A; Freedman JA; Olender J; Knapp S; Ching T; Garmire L; Patel V; Garcia-Blanco MA; Patierno SR; Lee NH
    Nat Commun; 2017 Jun; 8():15921. PubMed ID: 28665395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.
    Freedman JA; Wang Y; Li X; Liu H; Moorman PG; George DJ; Lee NH; Hyslop T; Wei Q; Patierno SR
    Carcinogenesis; 2018 Jul; 39(7):879-888. PubMed ID: 29726910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
    Lv S; Ji L; Chen B; Liu S; Lei C; Liu X; Qi X; Wang Y; Lai-Han Leung E; Wang H; Zhang L; Yu X; Liu Z; Wei Q; Lu L
    Oncogene; 2018 Mar; 37(10):1354-1368. PubMed ID: 29269867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of alternative splicing across multiple transcriptomic cohorts reveals prognostic signatures in prostate cancer.
    Mou Z; Spencer J; McGrath JS; Harries LW
    Hum Genomics; 2023 Nov; 17(1):97. PubMed ID: 37924098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative splicing in prostate cancer progression and therapeutic resistance.
    Rawat C; Heemers HV
    Oncogene; 2024 May; 43(22):1655-1668. PubMed ID: 38658776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research progress of SOX9 in the evolution of prostate cancer].
    Dong JT; Kang SS; Cao FH
    Zhonghua Nan Ke Xue; 2023 Jun; 29(6):552-556. PubMed ID: 38602730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant RNA Splicing in Cancer and Drug Resistance.
    Wang BD; Lee NH
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets.
    Alors-Pérez E; Blázquez-Encinas R; Moreno-Montilla MT; García-Vioque V; Jiménez-Vacas JM; Mafficini A; González-Borja I; Luchini C; Sánchez-Hidalgo JM; Sánchez-Frías ME; Pedraza-Arevalo S; Romero-Ruiz A; Lawlor RT; Viúdez A; Gahete MD; Scarpa A; Arjona-Sánchez Á; Luque RM; Ibáñez-Costa A; Castaño JP
    Mol Oncol; 2024 May; ():. PubMed ID: 38790138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variation of
    Cheng Y; Shi R; Ben S; Chen S; Li S; Xin J; Wang M; Cheng G
    J Biomed Res; 2024 May; ():1-11. PubMed ID: 38808547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
    Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
    Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer.
    Sáez-Martínez P; Jiménez-Vacas JM; León-González AJ; Herrero-Aguayo V; Montero Hidalgo AJ; Gómez-Gómez E; Sánchez-Sánchez R; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
    López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
    Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; Venegas-Moreno E; L-López F; Fanciulli A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Dios E; Blanco-Acevedo C; Solivera J; Granata R; Kineman RD; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
    Neuroendocrinology; 2020; 110(11-12):1028-1041. PubMed ID: 31940630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Shah K; Gagliano T; Garland L; O'Hanlon T; Bortolotti D; Gentili V; Rizzo R; Giamas G; Dean M
    Oncogene; 2020 Sep; 39(39):6172-6189. PubMed ID: 32820253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles and mechanisms of alternative splicing in cancer - implications for care.
    Bonnal SC; López-Oreja I; Valcárcel J
    Nat Rev Clin Oncol; 2020 Aug; 17(8):457-474. PubMed ID: 32303702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth.
    Li WJ; He YH; Yang JJ; Hu GS; Lin YA; Ran T; Peng BL; Xie BL; Huang MF; Gao X; Huang HH; Zhu HH; Ye F; Liu W
    Nat Commun; 2021 Mar; 12(1):1946. PubMed ID: 33782401
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.